DEF: Pelthos Therapeutics Seeks Shareholder Approval for Key Governance, Financing Measures

Pelthos Therapeutics Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and approve a critical waiver for its $18 million convertible note financing, which could lead to significant shareholder dilution.

Summary

• Pelthos Therapeutics Inc. will hold its 2025 Annual Meeting of Shareholders virtually on December 17, 2025, at 9:00 am Eastern Time.
• Shareholders will vote on three key proposals: electing seven directors, waiving the NYSE American Exchange Cap for the Senior Secured Convertible Notes financing, and ratifying CBIZ CPAs P.C. as the independent auditor for fiscal year 2025.
• The Board unanimously recommends voting FOR all director nominees and FOR Proposals No. 2 and No. 3.
• The company completed a merger with LNHC, a wholly-owned subsidiary of Ligand, on July 1, 2025, and subsequently changed its name from Channel Therapeutics Corporation to Pelthos Therapeutics Inc.
• A PIPE Financing closed on July 1, 2025, raising approximately $50.1 million in gross proceeds through the issuance of Series A Preferred Stock.
• A Convertible Note Financing closed on November 6, 2025, raising approximately $18.0 million in gross proceeds through the issuance of Senior Secured Convertible Notes. These notes carry an 8.5% annual interest rate (18.0% on default) and mature on November 6, 2027.
• The Convertible Notes are convertible into common stock at a price of $34.442 per share, which could be reduced to $29.73 per share with shareholder approval, or automatically adjusted to the average volume-weighted average price (VWAP) at maturity under certain conditions.
• Approval of the Exchange Cap waiver (Proposal No. 2) would allow the company to issue shares exceeding 19.99% of its pre-transaction outstanding common stock, leading to dilution for existing shareholders.
• If Proposal No. 2 is not approved, the company faces a cash penalty of 0.5% on unissued shares and may be limited in its ability to restructure or raise additional capital.
• The company effected a one-for-nine reverse stock split on February 15, 2024, and a one-for-ten reverse stock split on July 1, 2025.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the company successfully secured significant financing through the PIPE and Convertible Notes, the need for these raises and the associated potential for substantial shareholder dilution (up to 34.9% for non-affiliates from the Convertible Notes alone, plus the PIPE conversion) are significant concerns. The potential for further conversion price reductions and the high default interest rate on the convertible notes highlight financial pressures. The multiple reverse stock splits also suggest past performance challenges. The new management team and diversified product focus offer potential, but the immediate financial implications are dilutive and carry risk.

Positives

• Successful completion of a merger with LNHC, expanding the company's business plan into biopharmaceuticals.
• Secured approximately $50.1 million in gross proceeds from a PIPE Financing.
• Secured an additional $18.0 million in gross proceeds from a Convertible Note Financing, providing capital for operations.
• The Board has established an audit, compensation, and nominating and corporate governance committee, indicating adherence to corporate governance best practices.
• The company has a diversified pipeline of non-opioid pain treatment therapies and therapeutic options for related conditions through the Benuvia License Agreement.

Negatives

• The Convertible Note Financing, if the Exchange Cap waiver is approved, will result in significant dilution for existing shareholders, as the conversion could represent approximately 17.1% of total outstanding common stock and 34.9% of non-affiliate held common stock.
• Failure to approve the Exchange Cap waiver (Proposal No. 2) would require the company to pay a cash penalty of 0.5% on unissued shares and could limit future financing and restructuring options.
• The potential reduction of the Convertible Notes' conversion price from $34.442 to $29.73 per share, or even lower to VWAP at maturity under certain conditions, would further exacerbate shareholder dilution.
• The company has undergone two reverse stock splits (one-for-nine on Feb 15, 2024, and one-for-ten on July 1, 2025), which often indicate underlying stock price weakness or efforts to maintain listing requirements.
• A default judgment against Chromocell Holdings (a related party) resulted in the transfer of Channel common stock, indicating past financial or legal issues within related entities.
• The company's former Chief Medical Officer, Dr. Eric Lang, and former Chief Executive Officer, Christian Kopfli, had their employment terminated, which could signal management instability or strategic shifts.

Risks

• Shareholder Dilution: Approval of Proposal No. 2 will result in significant dilution of existing shareholders' economic and voting interests due to the potential issuance of a large number of Common Stock shares upon conversion of the Convertible Notes.
• Financial Penalties and Limited Capital Access: If Proposal No. 2 is not approved, the company will incur a cash penalty of 0.5% on unissued shares and may face limitations in restructuring or refinancing its obligations under the Convertible Notes or raising additional capital on favorable terms.
• Conversion Price Adjustment: The Convertible Notes' conversion price may automatically adjust downwards to $29.73 per share or to the average volume-weighted average price (VWAP) at maturity under certain conditions, leading to further dilution.
• Dependence on Related Parties: The company has engaged in numerous related-party transactions, including significant financing from Ligand and other entities with board representation, which could create potential conflicts of interest or undue influence.
• Operational Risks: The company's business plan now includes commercializing innovative biopharmaceutical products, which inherently carries risks related to development, regulatory approval, market acceptance, and competition.
• Liquidity Risk: The need for the Convertible Note Financing and the terms associated with it (e.g., high interest rate on default, potential for cash penalties) suggest ongoing capital needs and potential liquidity challenges.

Future Outlook

The company's future outlook is tied to the successful commercialization of its biopharmaceutical products, including ZELSUVMI for molluscum contagiosum and the Spray Formulations for pain and related conditions. The company also aims to independently fund and develop its historical assets related to the NaV1.7 sodium-ion channel for various pain treatments. The ability to raise additional capital and manage its debt obligations, particularly the Convertible Notes, will be critical for its strategic execution.

Management Comments

• The Board recommends that you vote FOR each director nominee and FOR each of Proposals No. 2 and No. 3.
• The Board believes that it should have the flexibility to make these determinations [on CEO/Chairman roles] at any given point in time in the way that it believes best to provide appropriate leadership for the Company at that time.
• The Board unanimously recommends a vote to approve the Exchange Cap waiver in connection with the Convertible Note Financing.
• The Board of Directors unanimously recommends a vote for the ratification of the selection of CBIZ as the Company's independent registered public accountants for the fiscal year ending December 31, 2025.

Industry Context

Pelthos Therapeutics operates in the biopharmaceutical sector, focusing on dermatologic infectious diseases (ZELSUVMI for molluscum contagiosum) and non-opioid pain treatments (Spray Formulations, NaV1.7 program). The industry is characterized by high R&D costs, lengthy regulatory processes, and intense competition. The company's recent merger with LNHC and licensing agreements indicate a strategy to expand its pipeline and commercialization capabilities, aligning with a trend of smaller biotechs seeking strategic partnerships or mergers to advance product portfolios. The capital raises reflect the significant funding requirements typical for companies in this stage of development.

Comparison to Industry Standards

• NA. The filing is a proxy statement focused on corporate governance and financing proposals, not a performance report that would allow for specific comparisons to industry benchmarks or competitor results.

Management Changes

Corporate Governance

Legal Proceedings

• A default judgment was issued against Chromocell Holdings (a related party) on November 25, 2024, by the Supreme Court of the State of New York, County of New York, regarding the default of a secured promissory note, resulting in the transfer of 747,187 shares of Channel common stock and 2,600 shares of Series C Preferred Stock to Alexandra Wood (Canada) Inc. (AWI).

Related Party Transactions

• Chromocell Holdings: Provided advances to Channel (May 2021-Aug 2022), contributed therapeutics business assets to Channel, reassumed $1.6 million in liabilities, waived $0.6 million cash payment, and received 2,600 shares of Series C Preferred Stock. Forfeited 133,745 shares of Channel common stock due to non-funding in April Bridge Financing. Shares transferred to AWI due to default judgment.
• Todd Davis (Director): Provided a $175,000 promissory note (Director Note) to Channel, which was repaid by issuing 29,167 shares of Common Stock. Also serves as Chairman and CEO of Benuvia Holdings, LLC, the ultimate parent company of Benuvia Operations LLC, with which Pelthos has an exclusive licensing agreement.
• April Bridge Financing (April 17, 2023): $389,757 aggregate principal from pre-existing shareholders including Chromocell Holdings, Boswell Prayer Ltd., Motif Pharmaceuticals Ltd, Aperture Healthcare Ventures Ltd., MDB Merchants Park LLC, Balmoral, and AME Equities LLC.
• September Bridge Financing (September 1, 2023): $198,128 aggregate principal from pre-existing shareholders including Aperture Healthcare Ventures Ltd., MDB Merchants Park LLC, Balmoral, and AME Equities LLC.
• October Promissory Notes (October 12, 2023): $210,000 face amount from four existing investors, repaid in February 2024.
• Rights Offering (November 22 December 1, 2023): Pre-existing shareholders, including Aperture Healthcare Ventures Ltd., MDB Merchants Park LLC, Balmoral, AME Equities LLC, and the Knuettel Trust (related to CFO Francis Knuettel II), participated.
• Benuvia License Agreement (December 23, 2023): Exclusive worldwide rights for Spray Formulations from Benuvia Operations LLC. Channel issued 384,226 shares of common stock to Benuvia.
• Ligand Pharmaceuticals Incorporated: Parent company of LNHC, which merged with Pelthos. LNHC assigned NITRICIL platform and ZELSUVMI assets to Ligand, then licensed ZELSUVMI back from Ligand (Amended Sato Agreement) with 13% royalty payments and $10 million milestones. LNHC provides development/manufacturing services to Ligand (Master Services Agreement). Ligand provided an $18.0 million revolving bridge note to LNHC. Ligand was a major investor in the PIPE Financing ($31,279 shares of Series A Preferred Stock) and the Convertible Note Financing ($9.0 million principal). Ligand also receives royalties on Channel Covered Products.
• PIPE Financing (July 1, 2025): Investors included Ligand, Camden Capital LLC (related to CFO Francis Knuettel II), Balmoral Financial Group LLC (related to Director Ezra Friedberg), and Key Recovery Group LLC (related to Director Ezra Friedberg).
• Nomis RoyaltyVest LLC (NRV) and Madison Royalty LLC: Entered into Purchase and Sale Agreements with the company for portions of revenue payments and royalties on ZELSUVMI and Channel Covered Products. NRV, Ligand, and Madison also received amended royalty terms on Channel Covered Products and ZELSUVMI as an inducement for the November 2025 Securities Purchase Agreement.
• Convertible Note Financing (November 6, 2025): Investors included Ligand ($9.0 million principal) and Balmoral ($250,000 principal). These investors received a 5.0% royalty on XepiTM net sales and a share of Sato Payments.

Stakeholder Impact

• Shareholders: Significant potential for dilution of economic and voting interests if Proposal No. 2 (Exchange Cap waiver) is approved and Convertible Notes convert, especially given the potential for a reduced conversion price. Existing shareholders' ownership percentage will decrease.
• Employees/Management: New employment agreements and equity awards for key executives (Plesha, Knuettel, Rangarao) provide incentives and compensation. Termination of former executives (Lang, Kopfli) indicates strategic shifts.
• Creditors (Convertible Note Holders): The Convertible Notes are senior secured and carry a high interest rate, providing strong protection. They also benefit from royalties on XepiTM and Sato Payments.
• Customers: The company's focus on commercializing biopharmaceutical products for molluscum contagiosum and pain treatments aims to provide new therapeutic options.
• Suppliers (Benuvia): Benuvia Operations LLC benefits from an exclusive supply agreement for the Spray Formulations and received shares of common stock.

Next Steps

• Hold the 2025 Annual Meeting of Shareholders on December 17, 2025, to vote on director elections, the Exchange Cap waiver, and auditor ratification.
• If Proposal No. 2 is approved, the company will be able to issue the maximum number of shares under the Convertible Notes, potentially at a reduced conversion price.
• If Proposal No. 2 is not approved, the company will incur cash penalties and may face limitations in future financing or restructuring.
• The company is obligated to file a resale registration statement with the SEC covering shares of Common Stock issuable upon conversion of the Series A Preferred Stock from the PIPE Financing.
• The company is required to prepare and file a resale registration statement with the SEC covering shares of Common Stock issuable upon conversion of the Convertible Notes on or prior to January 5, 2026.
• Ligand and LNHC will negotiate in good faith a development and funding agreement for LNHC to obtain rights to develop and commercialize the SB207 product program within one year of March 24, 2025.
• The Board is evaluating the adoption of a policy concerning the timing of equity awards relative to material non-public information disclosures.

Key Dates

Recommendation

The company is undergoing a significant transformation following its merger and has secured substantial capital through PIPE and Convertible Note financings. While these financings provide necessary capital for advancing its biopharmaceutical pipeline, the potential for substantial shareholder dilution from the Convertible Notes, especially with the possibility of a reduced conversion price, presents a notable downside risk. The multiple reverse stock splits in recent history also raise concerns about long-term value creation. The new management team and diversified product focus offer potential, but the immediate future involves navigating dilution and executing on commercialization. A 'hold' recommendation is appropriate to observe how the company manages the dilution, integrates its new assets, and progresses with its commercialization efforts before making a more definitive investment decision.

Keywords

Pelthos Therapeutics, PTHS, SEC Filing, Proxy Statement, Annual Meeting, Shareholder Vote, Convertible Notes, Capital Raise, Dilution, Biopharmaceutical, Corporate Governance, NYSE American, Exchange Cap, ZELSUVMI, Xepi, Molluscum Contagiosum, Pain Treatment, Drug Development, Ligand Pharmaceuticals, Reverse Stock Split